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of other causes, and for 114 patients (3 %) cause of death 
was unknown. Median follow-up time was 7.6 years. After 
correction for overoptimism, the c-statistic of the predic-
tion model for prostate cancer-specific mortality was 0.78 
(95 % CI 0.74–0.82), compared to 0.78 (95 % CI 0.75–
0.81) for the risk classification system by Ash et al. The 
PREDICT model showed better calibration than the Ash 
risk classification system.
Conclusions The PREDICT model showed a good pre-
dictive accuracy and reliability. The PREDICT model 
might be a promising tool for physicians to predict disease-
specific survival prior to any generally accepted interven-
tion in patients with localized prostate cancer.
Keywords Grade · Prediction · Prostate cancer · PSA · 
Survival · T-stage
Introduction
Many models have been developed for risk stratification of 
patients with localized prostate cancer. Most nomograms 
incorporate pre-treatment PSA, clinical T-stage and biopsy 
Gleason score and are developed to predict biochemical 
failure for patients undergoing radical prostatectomy (RP), 
based on either pre-treatment clinical parameters [1–3] or 
post-treatment clinical parameters [4]. Other nomograms 
were developed for pre-treatment prediction of biochemi-
cal recurrence after external beam radiotherapy (EBRT) [5] 
or brachytherapy [6]. In some studies, prediction was based 
on patients treated with either RP or radiotherapy [7]. 
Although prediction of biochemical failure is important, 
survival outcome after biochemical recurrence is highly 
heterogeneous. Since disease-specific survival (DSS) 
is a more representative measure for significant disease 
Abstract 
Purpose Current models for prediction of prostate can-
cer-specific survival do not incorporate all present-day 
interventions. In the present study, a pre-treatment predic-
tion model for patients with localized prostate cancer was 
developed.
Methods From 1989 to 2008, 3383 patients were treated 
with I-125 brachytherapy (n = 1694), external beam 
radiotherapy (≥74 Gy, n = 336) or radical prostatectomy 
(n = 1353). Pre-treatment parameters (clinical T-stage, 
biopsy grade, PSA and age) were related to the hazard of 
mortality by multivariate Cox proportional hazard analysis. 
The PRetreatment Estimation of the risk of Death In Can-
cer of the prosTate (PREDICT) model was developed. The 
predictive accuracy of the model was assessed by calibra-
tion and discrimination and compared to the Ash risk clas-
sification system.
Results Of the 3383 patients analyzed, 2755 patients 
(81 %) were alive at the end of follow-up, 149 patients 
(4 %) died of prostate cancer and 365 patients (11 %) died 
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outcome, currently available biochemical risk nomograms 
are subject of discussion. Generally accepted present-day 
interventions for localized prostate cancer include I-125 
brachytherapy, RP or high-dose (≥74 Gy) EBRT [8–10]. 
Predictive models that have focused on survival as an out-
come measure do not include all present-day standard treat-
ment modalities [11–13]. Other models not included gen-
erally accepted current treatment options exclusively [14, 
15] and may therefore underestimate survival outcome 
after treatment in case less effective treatment modalities 
are included in the model design. In daily practice, due to 
its general applicability and easy use, risk categories (low, 
intermediate and high risk) instead of models are frequently 
used for determining the preferred treatment, for instance 
the scoring system of Ash and the D’Amico risk classifica-
tion system, both developed for prediction of biochemical 
recurrence [16, 17]. The risk category systems, however, do 
not allow prediction of individual patient survival outcome 
accurately [18]. In the present study, we aimed to develop a 
multivariate simple model for prediction of DSS and over-
all survival (OS) for localized prostate cancer patients prior 
to treatment with standard present-day interventions (RP, 
I-125 brachytherapy or high-dose EBRT). The following 
pre-treatment parameters were taken into account: clinical 




Clinical data were collected prospectively for patients 
treated in four university hospitals in The Netherlands and 
Belgium. Only patients treated up till 2008 were included 
in the present study, since sufficient follow-up was required 
to determine the 10-year probability of DSS and OS. From 
1989 to 2008, 1694 patients were treated at the UMC Utre-
cht Radiotherapy department with Iodine-125 brachyther-
apy (145 Gy). Implantations were performed according to 
the GEC-ESTRO guidelines [16]. In the years 1991 up till 
2008, 1353 patients were treated by prostatectomy at the 
Urology Department of the Radboud University Medical 
Center and the Netherlands Cancer Institute. The method 
of RP varied (open or laparoscopic or robot-assisted sur-
gery and nerve sparing or non-nerve sparing). Among these 
1353 patients, 335 (25 %) have been treated by adjuvant 
radiotherapy. Between 1998 and 2008, 336 patients were 
treated at the Ghent University Hospital using an intensity-
modulated radiotherapy technique (IMRT) to a dose of 
75–78 Gy.
Follow-up was measured until death or the latest known 
date of being alive (censor date). For the Dutch patients, 
survival status was retrieved through linkage with the 
Dutch Cancer Registry at the 31st of December 2012. For 
the Belgian patients, survival data were derived from the 
hospitals follow-up program and information from general 
physicians up till July 2013. Cause of death was retrieved 
from the medical charts.
Pre‑treatment predictors
Clinical data were derived from the patient’s medical 
records. Predictive clinical parameters were pre-specified 
based on the literature to prevent overfitting. Pretreat-
ment T-stage, grade (throughout time different Gleason 
score/tumor grade definitions have been used), initial PSA 
(iPSA) and age were incorporated in the PREDICT model. 
The American Joint Committee TNM classifications were 
used for determination of the T-stage [19]. To compare the 
predictive accuracy of the prognostic model with stand-
ard risk classification systems, patients were also classi-
fied by the Ash classification system (low-risk: T1c-T2a, 
PSA < 10 ng/mL, Gleason score ≤ 6; intermediate-risk: 
T2b-T2c, PSA 10–20 ng/mL, Gleason score 7; high-risk: 
≥T3a, PSA > 20 ng/mL, Gleason score ≥ 8 and/or ≥2 
intermediate-risk factors) [16].
Statistics
Kaplan–Meier analysis was used to estimate the actuarial 
DSS and OS. Baseline clinical characteristics and treatment 
modality are listed in Table 1. For 263 patients (7 %), one 
or more clinical parameters could not be retrieved (missing 
completely at random). Imputed missing clinical param-
eters were used by single imputation to prevent bias that 
would have occurred if only complete cases were used in 
the analysis [20]. When compared to the complete case 
Table 1  Clinical baseline 
characteristics of localized 
prostate cancer patients 
treated by brachytherapy, 
prostatectomy and external 
beam radiotherapy
Brachytherapy Prostatectomy EBRT Total
No. of patients 1694 1353 336 3383
Age (years, mean, range) 66 (43–91) 61 (42–80) 66 (41–80) 64 (41–91)
iPSA (ng/mL, median, range) 8.9 (0.3–100) 8.0 (0.1–157) 10.3 (0.04–302) 8.7 (0.04–302)
Clinical T-stage (median, range) cT1 (cT1–cT2c) cT2a (cT1–cT4) cT2a (cT1–cT4) cT1 (cT1–cT4)
Biopsy grade (median, range) 1 (1–3) 1 (1–3) 1 (1–3) 1 (1–3)
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analyses (Table 1), measures of central tendency and dis-
persion did not change significantly after imputation. Sur-
vival outcome was not imputed. The potential predictive 
parameters including T-stage (T1, T2 and ≥T3a), grade 
(1, 2 and 3), iPSA (log PSA) and age (age at treatment per 
5 years) were related to the hazard of mortality by means 
of multivariate Cox regression. Cox regression analysis 
was used for its ability to use censored observations. The 
values for iPSA and age automatically centered around the 
mean in the statistical analysis (therefore a negative num-
ber of points can be obtained). The ability of the model 
to discriminate between 10-year mortality or survival was 
calculated by means of c-statistics (Harrell’s concordance 
index). Since a model’s predictive accuracy is generally too 
optimistic, internal validation was performed by bootstrap-
ping (n = 200) to correct for this overfitting [21]. When 
using bootstrapping techniques, a model’s performance bet-
ter reflects the expected performance in a new population 
of patients. By means of shrinkage of the β-coefficients, the 
model was adjusted for this overoptimism. The final model 
was transformed into a clinical prediction rule based on 
the β-coefficients after shrinkage. The predictive accuracy 
of the final PREDICT model was evaluated by calibration 
(reliability) and discrimination. Calibration was assessed 
by plotting the deciles of the predicted risks of survival 
(median predicted percentage per decile) compared with 
the observed risks of survival (10-year DSS derived from 
actuarial life tables Kaplan–Meier analysis). The prognos-
tic performance of the PREDICT model was compared to 
that of the risk classification system for prostate cancer by 
Ash et al. [16].
Descriptive statistics and imputation were performed 
with the Statistical Package for Social Sciences (SPSS), 
version 20.0 (Chicago, IL, USA). All other statistical anal-
yses were carried out in the statistical package of R version 
2.10 (free software from the GNU project).
Results
Of the 3383 patients analyzed, 2755 patients (81 %) were 
alive at time of the censor date (31st of December 2012), 
618 patients (18 %) died, and for 10 patients follow-up 
of survival status could not be retrieved. Among the 618 
patients who did not survive, 149 patients (4 %) died 
of prostate cancer and 365 patients (11 %) died of non-
prostate cancer-related death, and for 114 patients (3 %) 
cause of death was not known. Median follow-up time was 
7.6 years (mean 8.3 years, SD 3.8 years), and 958 (28 %) 
patients reached 10.0-years follow-up (Table 2). According 
to the Ash risk classification system, 1198 (35 %) patients 
were categorized as having low-risk prostate cancer, 
1151(31 %) as having intermediate-risk disease and 1034 
(34 %) as having high-risk cancer.
Multivariate Cox regression analyses showed a c-statis-
tic (before bootstrapping) of the PREDICT model for pre-
diction of DSS of 0.81 (SD 0.03) and 0.68 (SD 0.02) for 
prediction of OS. In comparison, the corresponding c-sta-
tistics were 0.78 (SD 0.03) for DSS and 0.61 (SD 0.02) 
for OS for the risk classification system by Ash et al. The 
model was corrected for overoptimism (4 % for DSS and 
2 % for OS). For the Ash risk scoring system, 0 versus 1 % 
overoptimism was found. The adjusted β-coefficients for 
the PREDICT model for prediction of DSS after shrink-
age are shown in Table 3. The β-coefficients were rounded 
(multiplied by 10) to obtain a practical prediction rule. The 
c-statistics of the final PREDICT model after bootstrapping 
was 0.78 (95 % CI 0.74–0.82) for disease-specific survival. 
In comparison, a c-statistics of 0.78 (95 % CI 0.75–0.81) 
Table 2  Follow-up, disease-
specific and overall survival for 
patients with localized prostate 
cancer per treatment modality 
(brachytherapy, prostatectomy 
and external beam radiotherapy)
DSS disease-specific survival, OS overall survival
Brachytherapy Prostatectomy EBRT Total
No. of patients 1694 1353 336 3383
Follow-up (years, mean, 95 % CI) 7.9 (7.7–8.0) 9.1 (8.8–9.3) 7.1 (6.8–7.4) 8.3 (8.1–8.4)
10 year DSS (95 % CI) 91 % (90–92) 96 % (95–97) 93 % (90–95) 94 % (93–95)
10 year OS (95 % CI) 72 % (70–74) 87 % (85–89) 77 % (72–81) 79 % (78–80)
Table 3  Multivariable predictors (after shrinkage) of disease-specific 
survival for prostate cancer for the PREDICT model
Predictor HR 95 % CI
Age
 Age per 5 years 1.2 1.1–1.4
Pretreatment T-stage
 cT1 (reference)
 cT2 1.7 1.2–2.5
 ≥cT3a 1.8 0.9–3.6
Pretreatment grade
 G1 (reference)
 G2 2.9 2.0–4.2
 G3 3.6 2.1–6.1
Pretreatment PSA
 Log PSA 4.1 2.6–6.4
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was calculated for the Ash risk score. For prediction of 
overall survival, a c-statistic of 0.68 (95 % CI 0.65–0.70) 
was found for the PREDICT model, compared to 0.61 
(95 % CI 0.58–0.63) for the scoring system by Ash et al. 
Figure 1 shows the calibration of the predicted versus the 
observed risk of disease-specific survival (compared in risk 
strata) for the PREDICT model versus the Ash risk scoring 
system.
The total risk score of the PREDICT model for predict-
ing disease-specific survival is calculated by summing up 
the number of points obtained for each clinical factor (age 
+ T-stage + grade + iPSA = total score; Table 4). In this 
table, also the corresponding predicted 10-year disease-
specific survival rate can be found for different calculated 
total risk score categories. 
Discussion
After diagnosis of prostate cancer, patients are typically 
classified into risk categories bases on T-stage, Gleason 
score and pre-treatment PSA level, most frequently by 
using the Ash or D’Amico risk classification system [16, 
17].
The PREDICT model was developed as an easy tool 
for use in clinical practice. The goal was to achieve a more 
reliable prediction of disease-specific survival outcome 
for individual patients than the existing three category risk 
classification systems. Both the PREDICT model and the 
Ash system have a good accuracy for pre-treatment predic-
tion of DSS in non-metastasized prostate cancer (c-statistic 
0.78). The PREDICT model, however, had a better calibra-
tion performance (reliability) than the Ash risk classifica-
tion system. In other words, the predicted 10-year DSS is 
closer to the observed 10-year Kaplan–Meier derived DSS 
for the PREDICT model than for the Ash risk classification.
Since the model was developed on patients treated 
by well-established present-day types of treatment only 
(brachytherapy, high-dose EBRT, RP), this model will be 
applicable to the majority of prostate cancer patients. Accu-
rate prediction of treatment outcome is essential for patient 
counseling. The PREDICT model was compared to the Ash 




























Fig. 1  Calibration plots for prediction of disease-specific survival for 
the PREDICT model versus the Ash risk classification system. The 
predicted probability of survival based on the PREDICT model was 
compared to the observed survival. On the x-axis the predicted prob-
ability and on the y-axis the observed (actuarial life table) probability 
of 10-year disease-specific survival is shown. A slope of ‘1’ (refer-
ence line) is associated with optimal calibration
Table 4  Pre-treatment tool to predict the 10-year disease-specific survival for patients with localized prostate cancer (PREDICT model)
a Choose the closest value when the patient’s value lies between the given values
Age (years)a
 Value 44 49 54 59 64 69 74 79 84 89
 Score −8 −6 −4 −2 0 2 4 6 8 10
T-stage
 Value cT1 ≥cT2
 Score 0 6
Grade
 Value G1 G2 G3
 Score 0 11 13
iPSA (ng/mL)a
 Value 2 3 6 9 13 16 20 25 32 38 50 79
 Score −6 −4 −2 0 2 4 5 6 8 9 11 13
=
Total sum score
Total sum score <3 3–7 8–11 12–16 >16
10-year DSS (%) ≥93 88–92 82–87 72–81 ≤71
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used in clinical practice to decide on the treatment modality 
of preference. Overall survival could not be accurately pre-
dicted by the PREDICT model nor by the Ash risk classifi-
cation. This can be explained by the fact that prostate can-
cer mortality is only a small proportion of overall mortality, 
and only prostate cancer-related factors (not comorbidity 
parameters, except for patient age) were incorporated in the 
present model design. Walz et al. [22] did develop a model 
specifically for predicting 10-year general life expectancy 
with a high predictive accuracy (84 %) including age and 
Charlson comorbidity score. Other models have been used 
to predict life expectancy for non-prostate cancer-related 
causes [23].
As we expected, our predictive model allows for better 
individual prediction of DSS than the Ash risk score system. 
Risk classification relies on extrapolation of several risk fac-
tors in a heterogeneous patient group [18]. The strengths of 
the PREDICT model are the large patient numbers included. 
The median follow-up is 7.6 years (mean 8.3 years). Fur-
thermore, the whole spectrum of current interventions and 
only patients treated by well-established interventions (with 
assumed comparable cure rates) for prostate cancer were 
incorporated. The low-, intermediate- and high-risk patient 
groups according to the Ash risk score system were equally 
represented in the database. A possible limitation of the pre-
sent study is that for 3 % of patients cause of death could not 
be retrieved (equally divided among RP and brachytherapy 
patients, one missing cause of death among EBRT patients). 
Furthermore, patients were treated in different centers, with 
possible differences in pre-treatment imaging, number and 
system of taking biopsies and pathology evaluation (inter-
observer variability and Gleason score and tumor grade 
definition throughout time). Huang et al. [24] proposed inte-
gration of percentage of positive cores in risk stratification 
models. However, the percentage of positive cores was not 
available for a large number of patients in our database and 
could therefore not be used. The effect of treatment modal-
ity (brachytherapy, RP or high-dose radiotherapy) on DSS is 
not known, since no randomized controlled trials are availa-
ble up to date. The evidence available is conflicting and was 
based on retrospective data [25, 26]. In the present study, 
we have assumed that DSS is comparable in all three treat-
ment modalities and only dependent on risk factors. T-stage 
was the weakest predictor in the PREDICT model. T-stage 
and also tumor grading are known to be subject to under-
standing by random (and extended) biopsies and digital 
rectal examination/transrectal ultrasound when compared 
to post-prostatectomy pathology results [27, 28]. Adding 
MRI-based T-staging may increase the predictive accuracy 
of a predictive model. Prediction of biochemical recurrence 
after EBRT indeed improved by MRI imaging in addition 
to the Kattan model, when compared to the Kattan model 
alone [29].
Originally, pre-treatment risk category systems and 
models were developed to predict biochemical disease con-
trol. The Kattan, Stephenson and CAPRA models are the 
ones mostly used and have been extensively externally vali-
dated [1–3, 30]. A significant proportion of patients with 
biochemical recurrence, however, does not die from pros-
tate cancer; therefore, endpoints for unambiguous disease 
outcome such as survival or risk of metastatic disease are 
more relevant, but require longer follow-up time. Although 
many predictive models for prostate cancer exist, a minor-
ity of models is developed to predict survival and there is 
a lack of models for survival prediction incorporating all 
generally accepted present-day interventions [11–15]. Two 
CAPRA (Cancer of the Prostate Risk Assessment) score-
based models have been developed. The model design, 
however, did not exclusively include patients treated by 
current interventions [14, 15]. Particularly, EBRT dose 
and technique were heterogeneous in both studies. Radia-
tion therapy patients were included from 1987 on, and 
a lower dose to the prostate has been associated with 
an inferior tumor control and a higher risk of metastatic 
spread [10]. Indeed, the model showed a lower discrimina-
tive capacity for prediction of survival in patients treated 
by radiation compared to the prostatectomy group. In the 
study of Cooperberg et al. [15] also, patients managed by 
watchful waiting, active surveillance, primary hormonal 
therapy and cryotherapy were included, therefore biasing 
survival outcome to a lower survival rate when using the 
model for patients treated by more effective modalities. 
For the Kutikov et al. [14] model, discriminative capabil-
ity of the model was not described, which makes it hard to 
evaluate the internal validity of the model. Both CAPRA-
based models were not externally validated for prediction 
of prostate cancer-specific mortality. When developing a 
model, several important considerations should be taken 
into account [18]. External validation is the golden stand-
ard for evaluating reproducibility and accuracy. The PRE-
DICT model was based on large patient numbers with an 
intermediate follow-up time, has a good discrimination and 
calibration, but has to be validated in an external dataset 
before its clinical application. For (internal) validation pur-
poses [21], we did perform bootstrapping in anticipation of 
the external validation study, which will be performed on a 
different dataset.
Conclusion
Available pre-treatment models developed for prediction 
of survival after treatment for prostate cancer either not 
include all present-day interventions or include suboptimal 
treatment options or active surveillance. After external vali-
dation, the PREDICT model might be a promising tool for 
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physicians to predict survival preceding any current gen-
erally accepted intervention for non-metastasized prostate 
cancer.
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